Psychedelic Alpha’s Josh Hardman sits down with Jaskaran (‘Jaz’) Singh, Vice President Psychiatry Development at Neurocrine Biosciences. For the purposes of this conversation, however, we focus on Singh’s role in spearheading the development of esketamine for treatment-resistant depression, now marketed as Spravato. Here, we discuss how Singh’s early work assessing ketamine’s antidepressant…
